Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

← catalyst calendar

NCT06107413 · readout ≤ 134 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

280estimated

Sites

Countries

Belgium, Germany, Israel +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-11-12

actual

When the study began enrolling

Primary completion

Dec 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2026

estimated

The whole study's end, after follow-up

First posted

2023-10-30

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-12-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Unresectable Metastatic Colorectal Cancer

Interventions

Drug: ABBV-400
Drug: Bevacizumab
Drug: Folinic Acid
Drug: Fluorouracil
Drug: Irinotecan

Primary outcomes

what the primary-completion date above is the date OF

Percentage of Participants with Objective Response

measured Up to 24 Weeks

Progression Free Survival (PFS)

measured Up to 11 Months

Number of Participants with Adverse Events (AEs)

measured Up to 3 Years

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed